Mehta Analysis: Outlook For 2029

Looking forward means playing the long game in biopharma. In a decade's time, it will all be about knowing every protein the AI way, something which will have transformed the industry, believes Viren Mehta, founding partner of Mehta Partners LLC.

Proteins
AI will decipher protein folding and transform biopharma • Source: Shutterstock

While a great deal of ink is being spilled in crystal ball gazing about what the world holds for the New Year, the biopharma industry calls for thoughtful insights a decade out. We know that is how long it takes to achieve success in discovering, developing, and dominating with an innovative therapy. So, it is not a typo in the title above. Year-end reflection and the accelerating pace of scientific progress offer a timely opportunity to appreciate the increasingly exciting biopharma future. Information technology, especially its artificial intelligence (AI) frontier, and life science R&D are becoming one to address some of the most fundamental healthcare challenges.

It is now conceivable that the impact of life science innovations on the quality of our lives over the next...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from AI

More from Digital Technologies

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By 

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Menarini’s APAC CEO On Harnessing Digital Channels, RWE And BD Engine

 

In the final part of an interview with Scrip, Menarini’s Asia-Pacific CEO talks about the group’s digital capabilities, including their impact on a shortage issue in Australia, and leveraging RWE to inform healthcare practices across the region. The Italian company is also revving up its business development and alliance engine.